Last reviewed · How we verify
TBE vaccination and influenza vaccination
These are two separate vaccines that stimulate the immune system to produce antibodies and cellular immunity against tick-borne encephalitis virus and influenza virus respectively.
These are two separate vaccines that stimulate the immune system to produce antibodies and cellular immunity against tick-borne encephalitis virus and influenza virus respectively. Used for Prevention of tick-borne encephalitis, Prevention of seasonal influenza.
At a glance
| Generic name | TBE vaccination and influenza vaccination |
|---|---|
| Also known as | FSME-Immun ATC code: J07 BA1, Inflexal ATC code: J07 BB02 |
| Sponsor | Medical University of Vienna |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TBE vaccination uses inactivated tick-borne encephalitis virus to induce protective antibodies against the virus transmitted by tick bites in endemic regions. Influenza vaccination contains inactivated or attenuated influenza virus antigens to generate immune responses against seasonal influenza strains. Both work by priming the adaptive immune system to recognize and neutralize these pathogens upon exposure.
Approved indications
- Prevention of tick-borne encephalitis
- Prevention of seasonal influenza
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: